Durable, complete regression of metastatic cervical cancer can occur after a single infusion of human papillomavirus (HPV)-targeted tumor-infiltrating T cells (HPV-TILs), a new study published online this week in the Journal of Clinical Oncology has shown.
For the study, researchers sought to evaluate the effect of adoptive t-cell therapy on regression of metastatic cervical cancer.
Researchers enrolled nine patients with metastatic cervical cancer who had previously received platinum-based chemotherapy or chemoradiotherapy. All patients received lymphocyte-depleting chemotherapy, followed by an administration of aldesleukin.
Continue Reading
Then, patients received a single infusion of TILs selected when possible to target HPV E6 and E7.
Results showed that two patients achieved a complete response and one patient achieve a partial response.
Those who achieved a complete response were ongoing 22 and 15 months after treatment, respectively. The patient who achieved a partial response was 3 months in duration.
RELATED: Nomograms Predict Locally Advanced Cervical Cancer Recurrence, Patient Survival
Researchers also found that the frequency of HPV-reactive T cells in peripheral blood 1 month after treatment was positively associated with clinical response (P = 0.0238).
The authors conclude that continued investigation of this therapy is warranted.
Preliminary findings were presented at the 50th Annual Meeting of the American Society of Clinical Oncology in Chicago, Illinois.
Reference
